CEL-SCI Corporation (NYSE MKT: CVM) reported financial results today for the fiscal year ended September 30, 2014. The Company also reported key clinical and corporate developments achieved during, and subsequent to, fiscal 2014.
•CEL-SCI raised gross proceeds of $34.1 million during fiscal 2014 and an additional $7.0 million subsequent to the end of the fiscal year, to finance its expanding Phase III trial in the treatment of head and neck cancer.
Help employers find you! Check out all the jobs and post your resume.
